Ernexa Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $9.33 million. The enterprise value is $542,664.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 1.17 million shares outstanding. The number of shares has increased by 507.35% in one year.
| Current Share Class | 1.17M |
| Shares Outstanding | 1.17M |
| Shares Change (YoY) | +507.35% |
| Shares Change (QoQ) | +139.80% |
| Owned by Insiders (%) | 35.68% |
| Owned by Institutions (%) | 5.90% |
| Float | 668,713 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.89 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -375.37 |
Financial Efficiency
Return on equity (ROE) is -2,505.61% and return on invested capital (ROIC) is -303.08%.
| Return on Equity (ROE) | -2,505.61% |
| Return on Assets (ROA) | -81.20% |
| Return on Invested Capital (ROIC) | -303.08% |
| Return on Capital Employed (ROCE) | -143.03% |
| Weighted Average Cost of Capital (WACC) | 17.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.63M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -93,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.21% in the last 52 weeks. The beta is 2.47, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 2.47 |
| 52-Week Price Change | -90.21% |
| 50-Day Moving Average | 6.98 |
| 200-Day Moving Average | 22.61 |
| Relative Strength Index (RSI) | 45.01 |
| Average Volume (20 Days) | 5,024,685 |
Short Selling Information
The latest short interest is 162,618, so 13.94% of the outstanding shares have been sold short.
| Short Interest | 162,618 |
| Short Previous Month | 133,586 |
| Short % of Shares Out | 13.94% |
| Short % of Float | 24.32% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.14M |
| Pretax Income | -11.48M |
| Net Income | -11.40M |
| EBITDA | -10.08M |
| EBIT | -10.14M |
| Earnings Per Share (EPS) | -$27.49 |
Full Income StatementBalance Sheet
The company has $9.18 million in cash and $389,000 in debt, with a net cash position of $8.79 million or $7.53 per share.
| Cash & Cash Equivalents | 9.18M |
| Total Debt | 389,000 |
| Net Cash | 8.79M |
| Net Cash Per Share | $7.53 |
| Equity (Book Value) | 6.86M |
| Book Value Per Share | 5.88 |
| Working Capital | 6.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.22 million and capital expenditures -$39,000, giving a free cash flow of -$7.26 million.
| Operating Cash Flow | -7.22M |
| Capital Expenditures | -39,000 |
| Depreciation & Amortization | 55,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.26M |
| FCF Per Share | -$6.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
